The first report trying to explain this phenomenon from the perspective of loci undergoing loss of heterozygosity was published in 2016 [143] and described that after the treatment of seven patients with lung metastases by infusing ~1.11 × 1011 HLA-C*08:02—restricted tumor-infiltrating lymphocytes, six out of seven patients observed an objective regression on evaluation after 9-month therapy. The gene discussed is HLA-C; the disease is neoplasm.